|
|
HPLC Application Sheet
Nucleoside Analogs: Anticancer Prodrugs
Nucleoside analogue anticancer “pro” drugs are difficult to retain on conventional HPLC columns because of their highly
polar natures. With other HPLC Columns, ion pair reagents normally are used in order to achieve sufficient retention.
These additives interfere with MS detection and are not preferred. With the Cogent UDC-Cholesterol column, you can have
sufficient retention with a MS compatible mobile phase.
Click here to view
printable Application Sheet
|
Method Conditions
| Column |
Cogent UDC Cholesterol™, 4mm, 100A |
| Catalog No. |
69069-7.5P |
| Dimensions |
4.6 x 75mm |
| Mobile Phase |
60:40 acetonitrile/DI water + 0.5% formic acid
|
| Flow rate |
1.0 mL/minute |
| Injection Volume |
5 µL |
| Samples |
Proprietary Drugs
N1 - N3 nucleoside analogues
P1 - P3 other more hydrophobic proprietary compounds with polar functional groups
1 mg/L of each dissolved in the mobile phase |
| Detection |
UV 270nm - Diode Array |
Discussion
Cholesterol HPLC Columns are able to retain polar and nonpolar compounds in a single isocratic run. Adjustment of the
aqueous to organic ratio can be used to make either the polar or more hydrophobic compounds elute first. In the example
presented the more hydrophobic compounds are retained longer but retention and separation of the polar constituents is
still achieved.
If greater retention of the polar compounds is desired then a higher percentage of acetonitrile is required.
|
